AF4967

antibody from R&D Systems

Targeting: BCL9L B9L, Bcl9-2, DLNB11

Western blot (Supportive data in Antibodypedia)

Antibody Data

Product number

AF4967

Provider

R&D Systems

Product name

Human Bcl9-2 Antibody

Antibody type

Polyclonal

Description

Antigen Affinity-purified. Detects endogenous human Bcl9-2 in Western blots.

Reactivity

Human

Host

Sheep

Conjugate

Unconjugated

Antigen sequence

Q86UU0


Isotype

IgG

Vial size

100 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells.

Feng M, Jin JQ, Xia L, Xiao T, Mei S, Wang X, Huang X, Chen J, Liu M, Chen C, Rafi S, Zhu AX, Feng YX, Zhu D
Science advances 2019 May;5(5):eaau5240

---

Bcl9 and Pygo synergise downstream of Apc to effect intestinal neoplasia in FAP mouse models.

Mieszczanek J, van Tienen LM, Ibrahim AEK, Winton DJ, Bienz M
Nature communications 2019 Feb 13;10(1):724

Western blot

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Detection of Human Bcl9-2 by Western Blot. Western blot shows lysates of A172 human glioblastoma cell line and MCF-7 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Human Bcl9-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4967) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Bcl9-2 at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.